What Researchers Did
Researchers investigated the effects of hyperbaric oxygen therapy (HBOT) on inflammation biomarkers and symptoms in five patients with long COVID-19.
What They Found
Preliminary findings from five long COVID-19 patients suggest that hyperbaric oxygen therapy (HBOT) may counter oxidative stress and inflammation. This therapy potentially helps relieve persistent symptoms like fatigue and malaise, which are driven by inflammation.
What This Means for Canadian Patients
For Canadian patients experiencing persistent symptoms of long COVID-19, hyperbaric oxygen therapy (HBOT) could potentially offer a novel approach to reduce inflammation and improve quality of life. However, these preliminary findings require further validation in larger studies before widespread clinical application.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
The primary limitation of this study is its very small sample size of only five participants, making the findings preliminary and not generalizable.